Join

Compare · BCEL vs PFE

BCEL vs PFE

Side-by-side comparison of Atreca Inc. (BCEL) and Pfizer Inc. (PFE): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BCEL and PFE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • PFE is the larger of the two at $304.95B, about 4485.5x BCEL ($68.0M).
  • PFE has hit the wire 10 times in the past 4 weeks while BCEL has been quiet.
  • PFE has more recent analyst coverage (25 ratings vs 1 for BCEL).
MetricBCELPFE
Company
Atreca Inc.
Pfizer Inc.
Price
$0.18+0.40%
$26.98+1.20%
Market cap
$68.0M
$304.95B
1M return
-
-1.21%
1Y return
-
+17.13%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2019
News (4w)
0
10
Recent ratings
1
25
BCEL

Atreca Inc.

Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology. Atreca, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

PFE

Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Latest BCEL

Latest PFE